Note 14 - Segment Information

12 Months Ended

Apr. 30, 2014

Notes

Note 14 - Segment Information

 NOTE 14 - SEGMENT INFORMATION

The following information is presented in accordance with ASC Topic 280, “Segment Reporting”, for fiscal 2014 and 2013; we operated in three reportable business segments - (1) natural sweetener (stevioside), (2) traditional Chinese medicines and (3) corporate and other. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations. Condensed financial information with respect to these reportable business segments for the fiscal 2014 and 2013 is as follows:

	Fiscal year Ended April 30,
	2014	2013
Revenues:
Chinese medicine – third party	$     2,429,468	$     2,614,672
Chinese medicine – related party	0	0
Total Chinese medicine	2,429,468	2,614,672
Stevioside – third party	6,738,685	4,684,709
Stevioside – related party	3,705,504	2,503,147
Total Stevioside	10,444,189	7,187,856
Total segment and consolidated revenues	$   12,873,657	$     9,802,528
Interest expense:
Chinese medicine	$                     0	$                     0
Stevioside	120,144	27,793
Corporate and other	0	0
Total segment and consolidated interest expense	$        120,144	$          27,793
Depreciation and amortization:
Chinese medicine	$        164,122	$        445,318
Stevioside	2,000,460	1,401,442
Corporate and other	0	0
Total segment and consolidated depreciation and amortization	$     2,164,582	$     1,846,760
(Loss) income before income taxes:
Chinese medicine	$         (52,141)	$        207,879
Stevioside	(2,961,882)	(2,451,730)
Corporate and other	(51,798)	(1,730,289)
Total consolidated loss before income taxes	$   (3,065,821)	$   (3,974,140)

	April 30, 2014	April 30, 2013
Segment tangible assets:
Chinese medicine	$       605,918	$       644,073
Stevioside	14,332,440	15,081,311
Corporate and other	0	0
Total consolidated assets	$ 14,938,358	$ 15,725,384